Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

Boehringer Ingelheim4,575 enrolled

Overview

Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment

Study Type

OBSERVATIONAL

Enrollment

4,575

Conditions

Prostatic Hyperplasia

Interventions

ALNA®DRUG

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Suffering from BPS symptoms * Preceding treating with Terazosin for at least one month * IPSS sum score \>= 8 points prior to treatment start with ALNA® or complaints due to BP reduction by Terazosin * Indication for a switch to treatment with ALNA® according to its Summary of Product Characteristics (SPC) for a minimum period of one month Exclusion Criteria: * Patients fulfilling one of the general or specific contraindications listed in the ALNA® SPC, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredients of the product, orthostatic dysregulation or severe liver insufficiency could not be included in the Post Marketing Surveillance (PMS) study

Outcomes

Primary Outcomes

Change from baseline in International Prostatic Symptom Score (IPSS) by means on patient questionnaire